在肺状细胞癌中,EZH2抑制促进瘤免疫性
Tanner J DuCote1, Xiulong Song1, Kassandra J Naughton1
1Department of Toxicology and Cancer Biology, University of Kentucky, Lexington, Kentucky.
Cancer research communications
|January 24, 2024
概括
抑制zeste 2 (EZH2) 增强剂可能会改善肺状细胞癌中对免疫检查点抑制剂 (ICI) 的反应. 抑制EZH2可增强抗原呈现并增强抗瘤免疫力,支持LSCC的组合疗法.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
背景情况:
- 肺状细胞癌 (LSCC) 中对免疫检查点抑制剂 (ICI) 的耐药性与免疫抑制和抗原呈现不佳有关.
- 在瘤微环境中,zeste 2 (EZH2) 的表观遗传酶增强剂在调节基因表达方面发挥着作用.
研究的目的:
- 调查抑制EZH2是否可以增强LSCC中的ICI反应.
- 确定EZH2抑制影响瘤免疫性的分子机制.
主要方法:
- 使用LSCC细胞系和3D有机体的体外研究.
- 染色体免疫沉降测序 (ChIP-seq) 用于分析基因组修饰.
- 在体内研究使用本土和同源的LSCC模型治疗EZH2抑制剂和抗PD1免疫疗法.
- 单细胞RNA测序和免疫细胞分析.
主要成果:
- EZH2抑制增加了MHC类I和II (MHCI/II) 在mRNA和蛋白质水平上的表达.
- ChIP-seq证实了关键基因位置的基因标记改变,表明EZH2的调节作用.
- 结合EZH2抑制和抗PD1免疫疗法的联合治疗在体内显示出显著的瘤控制.
- 单细胞分析显示,免疫细胞的表型转移到一个不太抑制状态.
结论:
- EZH2抑制可以通过增强抗原呈现和调节LSCC中的免疫微环境来克服对ICI的抵抗.
- 这些发现支持将EZH2抑制剂与免疫疗法结合用于LSCC治疗的临床转化.
更多相关视频
05:00Author Spotlight: Enhancing Multicolor Fluorescence Localization in Lung Carcinoma Sample
Published on: November 21, 2023
1.8K
13:34A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
Published on: April 6, 2016
10.2K
相关概念视频
01:27Tumor Immunotherapy
526
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
526
02:49Cancer Therapies
7.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K
02:57Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K